Deepak Srivastava

CIK: 0001868501

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

TNYA

Tenaya Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (3 total)

TNYA
Tenaya Therapeutics, Inc.
May 28, 2026
Award(A)
Stock Option (Right to buy)
Direct
120K shares-
TNYA
Tenaya Therapeutics, Inc.
May 29, 2025
Award(A)
Stock Option (Right to buy)
Direct
107.4K shares-
TNYA
Tenaya Therapeutics, Inc.
Oct 18, 2024
Award(A)
Stock Option (Right to buy)
Direct
34K shares-

		Type	Shares	Price		Ownership
May 28, 2026	TNYA Tenaya Therapeutics, Inc.	Award(A) Stock Option (Right to buy)	120,000	-	-	Direct
May 29, 2025	TNYA Tenaya Therapeutics, Inc.	Award(A) Stock Option (Right to buy)	107,400	-	-	Direct
Oct 18, 2024	TNYA Tenaya Therapeutics, Inc.	Award(A) Stock Option (Right to buy)	34,000	-	-	Direct

1-3 of 3 transactions

About Srivastava Deepak

Srivastava Deepak (SEC CIK 0001868501) files insider reports with the SEC as Director of Tenaya Therapeutics, Inc. (TNYA).

Signal8 holds 3 ownership filings by Srivastava Deepak, all Form 4s, filed between Oct 21, 2024 and May 29, 2026. Those filings report 3 transactions, from Oct 18, 2024 to May 28, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Srivastava Deepak's filings is in SOUTH SAN FRANCISCO, CA.

Recent filings by Srivastava Deepak

May 28, 2026: Grant or award of TNYA derivative securities (Form 4, code A).
May 29, 2025: Grant or award of TNYA derivative securities (Form 4, code A).
Oct 18, 2024: Grant or award of TNYA derivative securities (Form 4, code A).

Other insiders filing for Tenaya Therapeutics, Inc. (TNYA)

Ali Faraz, Chief Executive Officer
Tingley Whittemore, Chief Medical Officer
Hyllengren Eric J, Chief Financial Officer
Williams R Sanders, Director
Walsh Jeffrey T., Director
Stehman-Breen Catherine, Director

How to read Form 4 transaction codes